Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow grows to $0
Q1 FY2026 financing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $77.43M.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $19.36M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 77.43M USD
- Year-over-year change
- -53.5%
- 4-year CAGR
- +6.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.43M | -53.5% |
| FY2024 | 2024-12-31 | 166.58M | +6005.9% |
| FY2023 | 2023-12-31 | (2.82M) | -428.6% |
| FY2022 | 2022-12-31 | (533.62K) | -100.9% |
| FY2021 | 2021-12-31 | 60.82M | — |
Financing Cash Flow vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +29.1% is the 7th highest of 10, against a peer median of +94.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $180.48M USD | +300903.0% | +202.6% | 10116.9% | |
| LTM Mar 2026 | $109.5M USD | +6044.6% | -1.3% | — | |
| LTM Mar 2026 | $77.43M USD | +29.1% | — | — | |
| LTM Mar 2026 | $71.76M USD | +44.8% | +112.4% | — | |
| LTM Mar 2026 | $44M USD | +352.1% | +11.6% | 1388.6% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $34.39M USD | -17.4% | +20.1% | — |
| LTM Mar 2026 | $20.24M USD | +94.0% | +64.8% | 109.9% | |
| FY2025 | €5.83M EUR | +197.0% | — | 209.2% | |
| LTM Mar 2026 | $2.68M USD | -95.0% | +225.3% | 511.0% | |
| LTM Mar 2026 | CHF 1.3M CHF | -109.0% | -9.9% | — | |
| Peer median (excluding CRBP) | — | +94.0% | +42.4% | 511.0% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | (2.74M) | (1.13M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.48M | 5.72M | 3.47M | 6.15M | 6.29M |
| Change in Working Capital | (15.7M) | (4.02M) | 4.09M | (5.58M) | 9.12M |
| Accounts Receivables | 1.62M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (5.96M) | (256.84K) | 1.03M | 1.6M | (2.35M) |
| Other Working Capital | (11.36M) | (3.77M) | 3.07M | (7.18M) | 11.47M |
| Other Non-Cash Items | 2.03M | 1.62M | 3.77M | 585K | (229K) |
| Operating Cash Flow | (48.18M) | (37.54M) | (36.1M) | (41.79M) | (64.49M) |
| Capital Expenditures | (54.17K) | (13.45K) | 3 | 0 | (7K) |
| Acquisitions (Net) | 0 | 8.1K | 0 | 0 | 0 |
| Purchases of Investments | (87.27M) | (86.34M) | (33.88M) | (180.8M) | (163.09M) |
| Sales of Investments | 13.88M | 116.42M | 69.53M | 59.49M | 161.46M |
| Other Investing Activities | 23.9K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (73.42M) | 30.07M | 35.64M | (121.31M) | (1.64M) |
| Debt Repayment | 57.78K | (533.62K) | (2.87M) | (15.48M) | 0 |
| Common Stock Issued | 62.59M | 0 | 53.4K | 182.06M | 77.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.82M) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 60.82M | (533.62K) | (2.82M) | 166.58M | 77.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (60.78M) | (8M) | (3.28M) | 3.47M | 11.29M |
| Free Cash Flow | (48.24M) | (37.56M) | (36.1M) | (41.79M) | (64.5M) |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.